Giovanni Gaudino

List of Publications by Year
in descending order

77 papers	6,330 citations	81900 39 h-index	106344 65 g-index
78 all docs	78 docs citations	78 times ranked	7492 citing authors

#	Article	IF	Citations
1	HMGB1 as a therapeutic target in disease. Journal of Cellular Physiology, 2021, 236, 3406-3419.	4.1	123
2	Recent Advances in the Genomic and Proteomic Researches on Mesothelioma: What Are Novel Insights into Mesothelioma Biology?. Respiratory Disease Series, 2021, , 137-149.	0.0	0
3	Biomolecular Pathways in Mesothelioma: What Is New Perspective on Biomolecular Research for Mesothelioma?. Respiratory Disease Series, 2021, , 43-52.	0.0	0
4	Asbestos-induced chronic inflammation in malignant pleural mesothelioma and related therapeutic approachesâ€"a narrative review. Precision Cancer Medicine, 2021, 4, 27-27.	1.8	15
5	BAP1 forms a trimer with HMGB1 and HDAC1 that modulates gene Ã— environment interaction with asbestos. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	14
6	Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 25543-25552.	7.1	53
7	Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer. Cancer Discovery, 2020, 10, 1103-1120.	9.4	144
8	Tumour predisposition and cancer syndromes as models to study geneâ€"environment interactions. Nature Reviews Cancer, 2020, 20, 533-549.	28.4	93
9	Mesothelioma developing in carriers of inherited genetic mutations. Translational Lung Cancer Research, 2020, 9, S67-S76.	2.8	19
10	How asbestos and other fibers cause mesothelioma. Translational Lung Cancer Research, 2020, 9, S39-S46.	2.8	49
11	Heterozygous germline BLM mutations increase susceptibility to asbestos and mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 33466-33473.	7.1	30
12	Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?. Journal of Thoracic Oncology, 2019, 14, 157-159.	1.1	8
13	A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations. Journal of Clinical Oncology, 2018, 36, 3485-3494.	1.6	104
14	BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation. Nature, 2017, 546, 549-553.	27.8	308
15	FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model. Journal of Translational Medicine, 2017, 15, 58.	4.4	19
16	Germline BAP1 mutations induce a Warburg effect. Cell Death and Differentiation, 2017, 24, 1694-1704.	11.2	105
17	Diagnostic and prognostic biomarkers for malignant mesothelioma: an update. Translational Lung Cancer Research, 2017, 6, 259-269.	2.8	54
18	HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma. Oncotarget, 2017, 8, 22649-22661.	1.8	43

#	Article	IF	Citations
19	High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13432-13437.	7.1	130
20	Abstract 1179: Combined genetic and genealogic studies uncover a large BAP1 cancer syndrome kindred, tracing back nine generations to a common ancestor from the 1700s. Cancer Research, 2016, 76, 1179-1179.	0.9	2
21	Numerous Iron-Rich Particles Lie on the Surface of Erionite Fibers from Rome (Oregon, USA) and Karlik (Cappadocia, Turkey). Microscopy and Microanalysis, 2015, 21, 1341-1347.	0.4	20
22	Combined Genetic and Genealogic Studies Uncover a Large BAP1 Cancer Syndrome Kindred Tracing Back Nine Generations to a Common Ancestor from the 1700s. PLoS Genetics, 2015, 11, e1005633.	3.5	76
23	High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma. Journal of Thoracic Oncology, 2015, 10, 565-576.	1.1	282
24	Recent Insights Emerging from Malignant Mesothelioma Genome Sequencing. Journal of Thoracic Oncology, 2015, 10, 409-411.	1.1	19
25	Preclinical development of HIvax: Human survivin highly immunogenic vaccines. Human Vaccines and Immunotherapeutics, 2015, 11, 1585-1595.	3.3	14
26	Abstract 3944: High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma. , 2015, , .		0
27	HGF/Met Signaling Is a Key Player in Malignant Mesothelioma Carcinogenesis. Biomedicines, 2014, 2, 327-344.	3.2	12
28	Evaluation of clonal origin of malignant mesothelioma. Journal of Translational Medicine, 2014, 12, 301.	4.4	80
29	Increasing Dietary Selenium Elevates Reducing Capacity and ERK Activation Associated with Accelerated Progression of Select Mesothelioma Tumors. American Journal of Pathology, 2014, 184, 1041-1049.	3.8	16
30	The zeta potential of mineral fibres. Journal of Hazardous Materials, 2014, 276, 469-479.	12.4	68
31	Abstract 3188: Evaluation of clonal origin of malignant mesothelioma/polyclonal origin of malignant mesothelioma. , 2014, , .		0
32	Abstract 446: BAP1 mutation in mesothelioma and â€œBAP1 Cancer Syndromeâ€• , 2014, , .		0
33	Continuous Exposure to Chrysotile Asbestos Can Cause Transformation of Human Mesothelial Cells via HMGB1 and TNF-Î± Signaling. American Journal of Pathology, 2013, 183, 1654-1666.	3.8	88
34	BAP1 and cancer. Nature Reviews Cancer, 2013, 13, 153-159.	28.4	522
35	BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma. PLoS ONE, 2013, 8, e65489.	2.5	13
36	Fowlpoxâ€based survivin vaccination for malignant mesothelioma therapy. International Journal of Cancer, 2013, 133, 612-623.	5.1	16

#	Article	IF	Citations
37	Microâ€Raman spectroscopy identifies crocidolite and erionite fibers in tissue sections. Journal of Raman Spectroscopy, 2013, 44, 1440-1445.	2.5	11
38	Abstract 3588: Common and different effects induced in primary human mesothelial cells and mice exposed to chrysotile or crocidolite asbestos.. , 2013, , .		0
39	Abstract 5557: BoxA and ethyl pyruvate offer novel therapeutic approaches for human malignant mesothelioma.. , 2013, , .		0
40	CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma. Clinical Cancer Research, 2012, 18, 5352-5363.	7.0	78
41	Cancer Cell Secretion of the DAMP Protein HMGB1 Supports Progression in Malignant Mesothelioma. Cancer Research, 2012, 72, 3290-3301.	0.9	213
42	BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. Journal of Translational Medicine, 2012, 10, 179.	4.4	268
43	Abstract 1557: High mobility group box 1 secretion supports tumor progression of human malignant mesothelioma. , 2012, , .		0
44	Abstract 2514: CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma. , 2012, , .		0
45	MicroRNA regulation of core apoptosis pathways in cancer. European Journal of Cancer, 2011, 47, 163-174.	2.8	246
46	Simian virus 40 transformation, malignant mesothelioma and brain tumors. Expert Review of Respiratory Medicine, 2011, 5, 683-697.	2.5	40
47	Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13618-13623.	7.1	196
48	Ranpirnase Interferes with NF-ÂB Pathway and MMP9 Activity, Inhibiting Malignant Mesothelioma Cell Invasiveness and Xenograft Growth. Genes and Cancer, 2011, 2, 576-584.	1.9	28
49	Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics, 2011, 43, 1022-1025.	21.4	924
50	Abstract 2600: HMGB1, a potential new target for mesothelioma therapy. , 2011, , .		1
51	Abstract 4579: CSPG4 monoclonal antibodies inhibit the growth of human malignant mesothelioma. , 2011, , .		0
52	Gefitinib Targets EGFR Dimerization and ERK1/2 Phosphorylation to Inhibit Pleural Mesothelioma Cell Proliferation. Current Cancer Drug Targets, 2010, 10, 176-191.	1.6	21
53	MicroRNA Signature of Malignant Mesothelioma with Potential Diagnostic and Prognostic Implications. American Journal of Respiratory Cell and Molecular Biology, 2010, 42, 312-319.	2.9	155
54	Tissue Tropism of SV40 Transformation of Human Cells: Role of the Viral Regulatory Region and of Cellular Oncogenes. Genes and Cancer, 2010, 1, 1008-1020.	1.9	10

#	Article	IF	Citations
55	Estrogen Receptor-Î² Affects the Prognosis of Human Malignant Mesothelioma. Cancer Research, 2009, 69, 4598-4604.	0.9	87
56	Malignant pleural mesothelioma: current treatments and emerging drugs. Expert Opinion on Emerging Drugs, 2009, 14, 423-437.	2.4	33
57	RNF168, a new RING finger, MIU-containing protein that modifies chromatin by ubiquitination of histones H2A and H2AX. BMC Molecular Biology, 2009, 10, 55.	3.0	101
58	Molecular targets in cancer therapy: the Ron approach. Oncology Reviews, 2008, 1, 215-224.	1.8	2
59	The therapeutic potential of the novel ribonuclease ranpirnase (OnconaseÂ®) in the treatment of malignant mesothelioma. Oncology Reviews, 2008, 2, 61-65.	1.8	4
60	Targeting Î±7-nicotinic receptor for the treatment of pleural mesothelioma. European Journal of Cancer, 2008, 44, 2296-2311.	2.8	29
61	Mammalian Target of Rapamycin Contributes to the Acquired Apoptotic Resistance of Human Mesothelioma Multicellular Spheroids. Journal of Biological Chemistry, 2008, 283, 13021-13030.	3.4	130
62	Advances in the systemic therapy of malignant pleural mesothelioma. Nature Clinical Practice Oncology, 2008, 5, 136-147.	4.3	124
63	Imatinib Mesylate Enhances Therapeutic Effects of Gemcitabine in Human Malignant Mesothelioma Xenografts. Clinical Cancer Research, 2008, 14, 541-548.	7.0	65
64	Bortezomib Inhibits Nuclear Factor-ÎºBâ€“Dependent Survival and Has Potent In vivo Activity in Mesothelioma. Clinical Cancer Research, 2007, 13, 5942-5951.	7.0	90
65	Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed. Thorax, 2007, 62, 690-695.	5.6	46
66	Alpha- and betapapillomavirus E6/E7 genes differentially modulate pro-inflammatory gene expression. Virus Research, 2007, 124, 220-225.	2.2	38
67	Geldanamycins Trigger a Novel Ron Degradative Pathway, Hampering Oncogenic Signaling*. Journal of Biological Chemistry, 2006, 281, 21710-21719.	3.4	25
68	SV40-Dependent AKT Activity Drives Mesothelial Cell Transformation after Asbestos Exposure. Cancer Research, 2005, 65, 5256-5262.	0.9	81
69	Cellular and molecular facets of keratinocyte reepithelization during wound healing. Experimental Cell Research, 2005, 304, 274-286.	2.6	329
70	c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene, 2003, 22, 3669-3679.	5.9	47
71	Simian virus 40 infectionin lymphoproliferative disorders. Lancet, The, 2003, 361, 88-89.	13.7	52
72	Transforming growth factor-Î² released by PPD-presenting malignant mesothelioma cells inhibits interferon-Î³ synthesis by an anti-PPD CD4+ T-cell clone. International Journal of Molecular Medicine, 2003, 11, 161.	4.0	3

#	Article	IF	Citations
73	The Presence of Simian-Virus 40 Sequences in Mesothelioma and Mesothelial Cells Is Associated with High Levels of Vascular Endothelial Growth Factor. American Journal of Respiratory Cell and Molecular Biology, 2002, 26, 189-193.	2.9	67
74	Macrophage Stimulating Protein (MSP) evokes superoxide anion production by human macrophages of different origin. British Journal of Pharmacology, 2001, 134, 1285-1295.	5.4	51
75	The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site. Oncogene, 2000, 19, 5208-5211.	5.9	17
76	Point mutations in the tyrosine kinase domain release the oncogenic and metastatic potential of the ron receptor. Oncogene, 1998, 17, 741-749.	5.9	88
77	In Vivo Activation ofmetTyrosine Kinase by Heterodimeric Hepatocyte Growth Factor Molecule Promotes Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 1995, 15, 1857-1865.	2.4	89